



IFC

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Thunder Jalili

Serial No.: 10/822,568

Filed: April 12, 2004

For: QUERCETIN SUPPLEMENTATION
TO PREVENT AND TREAT
HYPERTENSION

Confirmation No.: 2642

Examiner: To be assigned


Group Art Unit: 1614

Attorney Docket No.: 0274-5928.1US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

August 26, 2004
Date


Signature

Betty Vowles
Name (Type/Print)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of U.S. patents are not being submitted pursuant to M.P.E.P. 609 III A(2). Copies of foreign patent documents and non-patent literature are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in

37 C.F.R. § 1.56(b). Further, no representation is made by Applicant herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
US-6,248,375	06-19-2001	Gilles et al.

Other Documents

AVIRAM et al., Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure, *Atherosclerosis*, 2001, pp. 195-98, Vol. 158.

BRODY et al., A randomized controlled trial of high dose ascorbic acid for reduction of blood pressure, cortisol, and subjective responses to psychological stress, *Psychopharmacology*, 2002, pp. 319-24, Vol. 159.

DURANTE et al., Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats, *British Journal of Pharmacology*, 2001, pp. 117-24, Vol. 133.

GALLEY et al., Combination oral antioxidant supplementation reduces blood pressure, *Clinical Science*, 1997, pp. 361-65, Vol. 92.

GRAEFE et al., Pharmacokinetics and Bioavailability of Quercetin Glycosides in Humans, *Herbal Medicine*, 2001, pp. 492-99, Vol. 41.

JALILI et al., PKC translocation without changes in G α and PLC- β protein abundance in cardiac hypertrophy and failure, *American Physiological Society*, pp. H2298-H2304.

KOBA et al., Effects of alpha-Tocopherol and Tocotrienols on Blood Pressure and Linoleic Acid Metabolism in the Spontaneously Hypertensive Rat (SHR), *Biosci. Biotech. Biochem.*, 1992, pp. 1420-23, Vol. 56, No. 9.

NAGUIB, A Fluorometric Method for Measurement of Oxygen Radical-Scavenging Activity of Water-Soluble Antioxidants, *Analytical Biochemistry*, 2000, pp. 93-98, Vol. 284.

NEWAZ et al., Effect of gamma-Tocotrienol on Blood Pressure, Lipid Peroxidation and Total Antioxidant Status in Spontaneously Hypertensive Rats (SHR), *Clin. and Exper. Hypertension*, 1999, pp. 1297-1313, Vol. 21, No. 8.

MAKITA et al., Alterations of phosphoinositide-specific phospholipase C and protein kinase C in the myocardium of spontaneously hypertensive rats, *Basic Research in Cardiology*, 1990, pp. 435-43, Vol. 85.

MELINA et al., Prevalence of Left Ventricular Hypertrophy and Cardiac Arrhythmias in Borderline Hypertension, *American Journal of Hypertension*, 1992, pp. 570-73, Vol. 5.

OKAMOTO et al., Development of a Strain of Spontaneously Hypertensive Rats, March 1963, *Japanese Circulation Journal*, pp. 282-93, Vol. 27.

PEDRO-BOTET et al., Decreased endogenous antioxidant enzymatic status in essential hypertension, *Journal of Human Hypertension*, 2000, pp. 343-45, Vol. 14.

RIZZONI et al., Vascular Structural and Functional Alterations Before and After the Development of Hypertension in SHR, *The American Journal of Hypertension, Ltd.*, 1994, pp. 193-200, Vol. 7.

ROBA, The Use of Spontaneously Hypertensive Rats for the Study of Anti-Hypertensive Agents, *Laboratory Animal Science*, 1976, pp. 305-18, Vol. 26, No. 2.

TAKEISHI et al., Src and Multiple MAP Kinase Activation in Cardiac Hypertrophy and Congestive Heart Failure Under Chronic Pressure-overload: Comparison with Acute Mechanical Stretch, 2001, *J. Mol. Cell Cardiol.*, pp. 1637-48, Vol. 33.

VAZIRI et al., Effect of Antioxidant Therapy on Blood Pressure and NO Synthase Expression in Hypertensive Rats, December 2000, pp. 957-964.

VAZIRI et al., Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension, *Kidney International*, 1999, pp. 1492-98, Vol. 56.

VAZIRI et al., Induction of Oxidative Stress by Glutathione Depletion Causes Severe Hypertension in Normal Rats, *Hypertension*, 2000, pp. 142-46, Vol. 36.

Serial No.: 10/822,568

This Information Disclosure Statement is believed to be filed before the mailing date of a first Office Action on the merits; therefore, no fee is due.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'G. Scott Dorland', written in a cursive style.

G. Scott Dorland, Ph.D.
Registration No. 51,622
Attorney for Applicant(s)
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: August 26, 2004
GSD/bv

Enclosures: Form PTO/SB/08
Cited Documents

Document in ProLaw

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number	10/822.568
--------------------	------------

Filing Date	April 12, 2004
-------------	----------------

First Named Inventor	Thunder Jalili
----------------------	----------------

Group Art Unit	1614
----------------	------

Examiner Name	To be assigned
---------------	----------------

Attorney Docket Number	0274-5928.1US
------------------------	---------------

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/822,568
Filing Date	April 12, 2004
First Named Inventor	Thunder Jalili
Group Art Unit	1614
Examiner Name	To be assigned
Attorney Docket Number	0274-5928 IUS

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		AVIRAM et al., Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure, Atherosclerosis, 2001, pp. 195-98, Vol. 158.	
		BRODY et al., A randomized controlled trial of high dose ascorbic acid for reduction of blood pressure, cortisol, and subjective responses to psychological stress, Psychopharmacology, 2002, pp. 319-24, Vol. 159.	
		DURANTE et al., Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats, British Journal of Pharmacology, 2001, pp. 117-24, Vol. 133.	
		GALLEY et al., Combination oral antioxidant supplementation reduces blood pressure, Clinical Science, 1997, pp. 361-65, Vol. 92.	
		GRAEFE et al., Pharmacokinetics and Bioavailability of Quercetin Glycosides in Humans, Herbal Medicine, 2001, pp. 492-99, Vol. 41.	
		JALILI et al., PKC translocation without changes in G α and PLC- β protein abundance in cardiac hypertrophy and failure, American Physiological Society, pp. H2298-H2304.	
		KOBA et al., Effects of alpha-Tocopherol and Tocotrienols on Blood Pressure and Linoleic Acid Metabolism in the Spontaneously Hypertensive Rat (SHR), Biosci. Biotech. Biochem., 1992, pp. 1420-23, Vol. 56, No. 9.	
		NAGUIB, A Fluorometric Method for Measurement of Oxygen Radical-Scavenging Activity of Water-Soluble Antioxidants, Analytical Biochemistry, 2000, pp. 93-98, Vol. 284.	
		NEWAZ et al., Effect of gamma-Tocotrienol on Blood Pressure, Lipid Peroxidation and Total Antioxidant Status in Spontaneously Hypertensive Rats (SHR), Clin. and Exper. Hypertension, 1999, pp. 1297-1313, Vol. 21, No. 8.	
		MAKITA et al., Alterations of phosphoinositide-specific phospholipase C and protein kinase C in the myocardium of spontaneously hypertensive rats, Basic Research in Cardiology, 1990, pp. 435-43, Vol. 85.	
		MELINA et al., Prevalence of Left Ventricular Hypertrophy and Cardiac Arrhythmias in Borderline Hypertension, American Journal of Hypertension, 1992, pp. 570-73, Vol. 5.	
		OKAMOTO et al., Development of a Strain of Spontaneously Hypertensive Rats, March 1963, Japanese Circulation Journal, pp. 282-93, Vol. 27.	
		PEDRO-BOTET et al., Decreased endogenous antioxidant enzymatic status in essential hypertension, Journal of Human Hypertension, 2000, pp. 343-45, Vol. 14.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

3

Complete if Known

Application Number

10/822,568

Filing Date

April 12, 2004

First Named Inventor

Thunder Jalili

Group Art Unit

1614

Examiner Name

To be assigned

Attorney Docket Number

0274-5928 IUS

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		RIZZONI et al., Vascular Structural and Functional Alterations Before and After the Development of Hypertension in SHR, The American Journal of Hypertension, Ltd., 1994, pp. 193-200, Vol. 7.	
		ROBA, The Use of Spontaneously Hypertensive Rats for the Study of Anti-Hypertensive Agents, Laboratory Animal Science, 1976, pp. 305-18, Vol. 26, No. 2.	
		TAKEISHI et al., Src and Multiple MAP Kinase Activation in Cardiac Hypertrophy and Congestive Heart Failure Under Chronic Pressure-overload: Comparison with Acute Mechanical Stretch, 2001, J. Mol. Cell Cardiol., pp. 1637-48, Vol. 33.	
		VAZIRI et al., Effect of Antioxidant Therapy on Blood Pressure and NO Synthase Expression in Hypertensive Rats, December 2000, pp. 957-964.	
		VAZIRI et al., Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension, Kidney International, 1999, pp. 1492-98, Vol. 56.	
		VAZIRI et al., Induction of Oxidative Stress by Glutathione Depletion Causes Severe Hypertension in Normal Rats, Hypertension, 2000, pp. 142-46, Vol. 36.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.